Current characteristics and outcomes of Cytomegalovirus Reactivation in kidney transplant seropositive recipients in the era of prophylaxis treatment. Lesson from single Moroccan center experience - Rezzouk, Bouchra.; Bouattar, Tarik.; Belkadi, Bouchra.; Razine, Rachid.; Bayahia, Rabia.; Ouzeddoun, Naima.; Benamar, Loubna.; Rhou, Hakima.; Bouihat, Najat.; Ibrahimi, Azeddine; Seffar, Myriam.; Kabbaj, Hakima. (medRxiv, 2019)
Despite the use of antiviral prophylaxis, the active cytomegalovirus (CMV) replication is still occurred in the seropositive kidney recipients. The aim of this study was to assess the incidence of CMV reactivation and potential risk factors associated with CMV disease. Data of sixty kidney transplant recipients who had received CMV prophylaxis were obtained between 2013 and 2017. Quantitative nucleic acid amplification testing for CMV viraemia was assessed using Abbott RealTime Polymerase Chain Reaction (PCR). Among the seropositive recipients, cumulative incidence for reactivation was 63%. In patients with quantitative viraemia, the time of active replication was significantly lower compared to those with detectable viraemia (141.5 extpm 96.9 vs 294.1 extpm 112.6 days, P < 0.001). During prophylactic treatment, 46.7% of patients with quantifiable viraemia had experienced active replication and none among patients with detectable viraemia (P= 0.017). Importantly, symptomatic reactivation was significantly observed in the younger patients with higher peak viraemia compared to those with symptoms free (28.8 extpm 5.12 vs. 38.1 extpm 12.34 years, P= 0.007) and 3.8 extpm 1.59 vs. 2.4 extpm 0. 79 log10IU/ml, P = 0.003, respectively). Furthermore, the median duration of viraemia (21.2, vs. 13.4 days, P= 0.028) and period of CMV therapy (24.3 vs 12.3 days, P <0.001) were significantly longer for this group. In addition, intercurrent infections (75% vs. 23%, P = 0.028) and acute rejection (50 % vs 0%, P = 0.003) were significantly more frequent in symptomatic reactivation group. In addition, peak viral load was a potential risk factor for development of symptomatic reactivation with odds ratio 3.39, 95%CI=1.21-9.53, P = 0.02). In conclusion, CMV reactivation remains serious problem for seropositive recipients who were expected to be on antiviral prophylaxis. Patients with high level of viraemia may be at an increased risk of progression to CMV disease and adverse outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo specific funding for this research was provided.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.NAI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAll relevant data are within the manuscript.